Oncology Institute (TOIIW) Other Operating Expenses (2021 - 2026)

Oncology Institute has reported Other Operating Expenses for 6 years, with the latest figure at $124.8 million in Q1 2026.

• For the quarter ending Q1 2026, Other Operating Expenses rose 41.98% year-over-year to $124.8 million; the trailing twelve-month figure through Mar 2026 stood at $466.2 million (up 34.36% YoY), and the FY2025 full-year result was $429.3 million, up 25.33% from the prior year.
• Other Operating Expenses for Q1 2026 stood at $124.8 million, up from $119.9 million in the prior quarter.
• The five-year high for Other Operating Expenses was $124.8 million in Q1 2026, with the low at $43.5 million in Q1 2022.
• Historically, Other Operating Expenses has averaged $82.0 million across 5 years, with a median of $83.5 million in 2024.
• Annual changes were most pronounced in 2023 — Other Operating Expenses surged 83.14% — and 2024, when it advanced 4.75%.
• Oncology Institute's Other Operating Expenses stood at $66.5 million in 2022, then climbed by 8.59% to $72.2 million in 2023, then gained by 19.71% to $86.4 million in 2024, then surged by 38.78% to $119.9 million in 2025, then increased by 4.11% to $124.8 million in 2026.
• The last three Other Operating Expenses figures came in at $124.8 million (Q1 2026), $119.9 million (Q4 2025), and $118.4 million (Q3 2025), per Business Quant data.